PROM1 and neoplasm: The results in Supplementary Table S1 verified that CD133+ CSCs represent a small population in cultured cancer cell lines (0.1% to 2%), tumor xenografts (0.5% for H460 and A549, 3% for MDA-MB-231) and tumor tissues from patients with breast cancer (3.82%).